Detailed Narrative
Strong Q4 and Full Year FY26 Performance
Gland Pharma delivered robust financial results for Q4 FY26, with revenues reaching ₹17,428 million, marking a 22% year-on-year growth. Adjusted EBITDA for the quarter stood at ₹5,244 million, achieving a 30% margin, a 500 bps improvement from the previous year. For the full year FY26, revenue was ₹64,307 million (14.5% growth) and adjusted EBITDA was ₹16,826 million (26% margin), with adjusted PAT at ₹10,455 million (16% margin). This strong performance was attributed to new product launches, increased volumes, and operational efficiencies.
CDMO Business as a Key Growth Pillar
The CDMO business continues to be a significant growth driver, contributing 46% to total revenues in FY26 and growing at 28%. The company signed multiple new CDMO contracts, expanding its pipeline in oncology, peptides, and complex injectables. One major CDMO project is expected to commercialize in H2 FY28 with an estimated annual revenue potential of $25-30 million. In the GLP-1 space, 8 contracts have been signed, with an additional 6-7 expected soon, and current cartridge capacity stands at 140 million units.
Cenexi Turnaround and Integration
Cenexi demonstrated a strong turnaround, achieving EBITDA positivity with EUR 1 million in Q4 FY26 and an EUR 16 million improvement in full-year EBITDA. Q4 revenue for Cenexi was EUR 45 million, a 4% year-on-year growth. The company is integrating Cenexi into its business development, technology transfer, and shared functions, aiming for cross-selling benefits and larger multi-geography contracts. Cenexi is targeted to reach EUR 200 million in revenue and mid-to-high single-digit EBITDA by FY27.
Geographic Performance and Product Launches
The United States, Gland Pharma's largest market, saw Q4 revenues grow 26% YoY to ₹9,716 million, driven by 5 new product launches, including Dalbavancin and multivitamin. Europe and other regulated markets grew 11% in FY26 to ₹3,249 million. The Rest of the World markets grew 17% YoY in Q4 to ₹1,468 million, though impacted by the Middle East conflict. India revenues for Q4 were ₹670 million. Dalbavancin has been launched in both US and European markets, showing strong demand.
R&D and Capacity Expansion Investments
Gland Pharma spent ₹2,230 million on R&D in FY26, representing 5% of base business revenue, focusing on complex injectables and specialty platforms. The company filed 24 ANDAs, received 28 approvals, and launched 31 products in the U.S. To support demand and future growth, Gland Pharma plans a capex outlay of ₹2,000 crores over the next five years, with ₹500 crores projected for FY27. Investments include new ophthalmic lines, blow-fill-seal technology, and dedicated equipment for CDMO contracts.
Cost Efficiency and Margin Improvement
Ongoing cost efficiency initiatives, including yield improvement, alternate sourcing, energy optimization, and process efficiencies, contributed approximately 1-2% to margin improvement. The company is also investing in AI and automation across quality, R&D, and manufacturing to create structural efficiency advantages. Gross margins improved by 30 bps in Q4 to 66% and by 230 bps in FY26 to 65%, reflecting favorable product mix and operational efficiencies.